296 related articles for article (PubMed ID: 35051024)
1. Video-Urodynamic Characteristics and Predictors of Switching from Botulinum Neurotoxin a Injection to Augmentation Enterocystoplasty in Spinal Cord Injury Patients.
Lin CC; Kuo HC
Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051024
[TBL] [Abstract][Full Text] [Related]
2. Can clinical and urodynamic parameters predict the occurrence of neutralizing antibodies in therapy failure of intradetrusor onabotulinumtoxin A injections in patients with spinal cord injury?
Tiburtius C; Böthig R; Kowald B; Hirschfeld S; Thietje R
BMC Urol; 2020 Aug; 20(1):113. PubMed ID: 32741365
[TBL] [Abstract][Full Text] [Related]
3. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
[TBL] [Abstract][Full Text] [Related]
4. Real-World Data Regarding Satisfaction to Botulinum Toxin A Injection into the Urethral Sphincter and Further Bladder Management for Voiding Dysfunction among Patients with Spinal Cord Injury and Voiding Dysfunction.
Lee CL; Jhang JF; Jiang YH; Kuo HC
Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051007
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia.
Chen CY; Liao CH; Kuo HC
Spinal Cord; 2011 May; 49(5):659-64. PubMed ID: 21243000
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity.
Chen SF; Kuo HC
J Formos Med Assoc; 2015 Jul; 114(7):583-9. PubMed ID: 24262922
[TBL] [Abstract][Full Text] [Related]
7. Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder.
Chen SF; Chang CH; Kuo HC
Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27249005
[TBL] [Abstract][Full Text] [Related]
8. Botulinum Toxin Type A Injection After Failure of Augmentation Enterocystoplasty Performed for Neurogenic Detrusor Overactivity: Preliminary Results of a Salvage Strategy. The ENTEROTOX Study.
Michel F; Ciceron C; Bernuz B; Boissier R; Gaillet S; Even A; Chartier-Kastler E; Denys P; Gamé X; Ruffion A; Normand LL; Perrouin-Verbe B; Saussine C; Manunta A; Forin V; De Seze M; Grise P; Tournebise H; Schurch B; Karsenty G
Urology; 2019 Jul; 129():43-47. PubMed ID: 30926380
[TBL] [Abstract][Full Text] [Related]
9. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.
Linsenmeyer TA
J Spinal Cord Med; 2013 Sep; 36(5):402-19. PubMed ID: 23941788
[TBL] [Abstract][Full Text] [Related]
10. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.
Popat R; Apostolidis A; Kalsi V; Gonzales G; Fowler CJ; Dasgupta P
J Urol; 2005 Sep; 174(3):984-9. PubMed ID: 16094019
[TBL] [Abstract][Full Text] [Related]
11. A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics.
Álvares RA; Araújo ID; Sanches MD
BMC Urol; 2014 Aug; 14():66. PubMed ID: 25123234
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
[TBL] [Abstract][Full Text] [Related]
13. Satisfaction with Detrusor OnabotulinumtoxinA Injections and Conversion to Other Bladder Management in Patients with Chronic Spinal Cord Injury.
Chen SF; Jiang YH; Jhang JF; Kuo HC
Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051012
[TBL] [Abstract][Full Text] [Related]
14. Are 200 units of onabotulinumtoxin A sufficient for the suppression of neurogenic detrusor overactivity in individuals with established 300-unit botulinum toxin treatment? A retrospective cohort study.
Krebs J; Pannek J; Rademacher F; Wöllner J
World J Urol; 2021 Feb; 39(2):543-547. PubMed ID: 32322995
[TBL] [Abstract][Full Text] [Related]
15. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes.
Kalsi V; Apostolidis A; Popat R; Gonzales G; Fowler CJ; Dasgupta P
Eur Urol; 2006 Mar; 49(3):528-35. PubMed ID: 16426735
[TBL] [Abstract][Full Text] [Related]
16. Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity.
Gutiérrez-Martín P; Vírseda-Chamorro M; Salinas Casado J; Gómez-Rodríguez A; Esteban-Fuertes M
Actas Urol Esp; 2015 May; 39(4):217-21. PubMed ID: 25582926
[TBL] [Abstract][Full Text] [Related]
17. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
Chen G; Liao L
Int Urol Nephrol; 2011 Sep; 43(3):655-62. PubMed ID: 21110094
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
Kuo HC
Urology; 2008 Nov; 72(5):1056-60. PubMed ID: 18533231
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
Denys P; Del Popolo G; Amarenco G; Karsenty G; Le Berre P; Padrazzi B; Picaut P;
Neurourol Urodyn; 2017 Feb; 36(2):457-462. PubMed ID: 26756554
[TBL] [Abstract][Full Text] [Related]
20. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Giannantoni A; Mearini E; Del Zingaro M; Porena M
Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]